viewTissue Regenix Group PLC

Tissue Regenix Group - CE Mark awarded for OrthoPure XT

RNS Number : 4554O
Tissue Regenix Group PLC
01 June 2020

This announcement contains inside information

Tissue Regenix Group plc

CE Mark awarded for OrthoPure XT

Leeds, 1 June 2020 - Tissue Regenix Group (AIM:TRX) ("Tissue Regenix" or "The Group"), the regenerative medical devices company, today announces that OrthoPure XT has been awarded a CE Mark.

The CE mark has been awarded for revision of the anterior cruciate ligament (ACL) following re-rupture and additionally, permits use for the reconstruction of other knee ligaments, including multi-ligament procedures following trauma.

OrthoPure XT is a decellularised xenograft ligament that enables tissue regeneration, utilising the Group's patented dCELL® technology which originated from the University of Leeds. The CE mark was obtained following a single arm, non-comparative, prospective study undertaken by the Group over three years. The main outcome was confirmation of safety at two years, with maintenance of knee function.

Gareth Jones, Interim Chief Executive Officer, Tissue Regenix commented: "I am delighted that the company has been successful in being awarded a CE mark for OrthoPure XT, this represents an important milestone in our product portfolio evolution.  The Board remains committed to reviewing the overall strategy for both existing and potential products, to ensure cash resources are deployed efficiently and our corporate objectives are met."


The person responsible for this announcement is Gareth Jones, Interim CEO.


For more Information:


Tissue Regenix Group plc

Caitlin Pearson                                 Head of Communications  

Tel: 0330 430 3073



Stifel Nicolaus Europe Limited (Nominated Adviser and Broker)

Jonathan Senior / Alex Price / Ben Maddison

Tel:  0207 710 7600




FTI Consulting 

Simon Conway / Victoria Foster Mitchell / Mary Whittow

Tel: 0203 727 1000



About Tissue Regenix

Tissue Regenix is a leading medical devices company in the field of regenerative medicine. Tissue Regenix was formed in 2006 when it was spun-out from the University of Leeds, UK. The company's patented decellularisation ('dCELL®') technology removes DNA and other cellular material from animal and human soft tissue leaving an acellular tissue scaffold which is not rejected by the patient's body and can then be used to repair diseased or worn out body parts. Current applications address many critical clinical needs such as sports medicine, heart valve replacement and wound care.

In November 2012 Tissue Regenix Group plc set up a subsidiary company in the United States - 'Tissue Regenix Wound Care Inc.', January 2016 saw the establishment of joint venture GBM-V, a multi- tissue bank based in Rostock, Germany.

In August 2017 Tissue Regenix acquired CellRight Technologies®, a biotech company that specializes in regenerative medicine and is dedicated to the development of innovative osteoinductive and wound care scaffolds that enhance healing opportunities of defects created by trauma and disease. CellRight's human osteobiologics may be used in spine, trauma, general orthopedic, foot & ankle, dental, and sports medicine surgical procedures.




This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.

Quick facts: Tissue Regenix Group PLC

Price: 0.33

Market: AIM
Market Cap: £23.21 m

Create your account: sign up and get ahead on news and events


The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...



Tissue Regenix "advancing on many fronts" says CEO after SurgiPure FDA clearance

Antony Odell, chief executive at Tissue Regenix (LON:TRX), talks to Proactive Investors about the US FDA clearance for SurgiPure XD, a skin graft for hernias derived from pig tissue. The group, which already has experience of commercialising products in the US, is planning a commercial...

on 03/09/2016